Education
About Us
Working with TipRanks
Follow Us
Roche Holding AG (RHHBY)
OTHER OTC:RHHBY
RHHBY Stock Chart & Stats
$52.50
$0.20(0.55%)
At close: 4:00 PM EST
$52.50
$0.20(0.55%)
Day’s Range― - ―
52-Week Range$34.75 - $53.00
Previous CloseN/A
Volume3.10M
Average Volume (3M)2.61M
Market Cap
$333.99B
Enterprise Value$234.67B
Total Cash (Recent Filing)$12.03B
Total Debt (Recent Filing)$34.63B
Price to Earnings (P/E)30.6
Beta0.23
Next Earnings
Jan 29, 2026EPS Estimate
1.34Next Dividend Ex-DateN/A
Dividend Yield1.63%
Share Statistics
EPS (TTM)1.74
Shares Outstanding5,620,501,500
10 Day Avg. Volume2,447,535
30 Day Avg. Volume2,605,707
Financial Highlights & Ratios
PEG Ratio-0.88
Price to Book (P/B)6.35
Price to Sales (P/S)3.24
P/FCF Ratio13.38
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue5.04
Enterprise Value/Gross Profit6.85
Enterprise Value/Ebitda18.77
Forecast
1Y Price Target
$49.67Price Target Upside-5.39% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)3.08
Revenue Forecast (FY)$77.29B
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsEarly trontinemab data shows competitive amyloid clearance and improved ARIA rate versus peers, but clinical outcomes will determine success.
Financial PerformanceRoche's model was updated and numbers raised post recent business trends, with sales and EPS growth estimates increased.
Product EfficacyGazyva showed potential best-in-class profile in lupus nephritis and is likely to be the starter therapy of choice versus GSK's Benlysta.
Bears Say
Clinical Trial SafetyThere was a case of fatal cerebral macrohemorrhage in Part 2, leading to updated trial criteria to exclude patients with superficial siderosis.
Placebo ResponseThe high placebo response rate in males was notable, where placebo achieved a 66.7% complete renal response compared to 42.9% for Gazyva.
Roche Holding News
RHHBY FAQ
What was Roche Holding AG’s price range in the past 12 months?
Roche Holding AG lowest stock price was $34.75 and its highest was $53.00 in the past 12 months.
What is Roche Holding AG’s market cap?
Roche Holding AG’s market cap is $333.99B.
When is Roche Holding AG’s upcoming earnings report date?
Roche Holding AG’s upcoming earnings report date is Jan 29, 2026 which is in 32 days.
How were Roche Holding AG’s earnings last quarter?
Roche Holding AG released its earnings results on Jul 24, 2025. The company reported $1.742 earnings per share for the quarter, beating the consensus estimate of $1.689 by $0.053.
Is Roche Holding AG overvalued?
According to Wall Street analysts Roche Holding AG’s price is currently Overvalued.
Does Roche Holding AG pay dividends?
Roche Holding AG pays a Annually dividend of $0.856 which represents an annual dividend yield of 1.63%. See more information on Roche Holding AG dividends here
What is Roche Holding AG’s EPS estimate?
Roche Holding AG’s EPS estimate is 1.34.
How many shares outstanding does Roche Holding AG have?
Roche Holding AG has 5,620,501,500 shares outstanding.
What happened to Roche Holding AG’s price movement after its last earnings report?
Roche Holding AG reported an EPS of $1.742 in its last earnings report, beating expectations of $1.689. Following the earnings report the stock price went up 0.729%.
Which hedge fund is a major shareholder of Roche Holding AG?
Currently, no hedge funds are holding shares in RHHBY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Roche Holding Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$49.67 (-5.39% Downside)
$49.67 (-5.39% Downside)
Blogger Sentiment
Bullish
RHHBY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 5.6%
Last 30 Days ▲ 5.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.09%
12-Months-Change
Fundamentals
Return on Equity
31.98%
Trailing 12-Months
Asset Growth
11.69%
Trailing 12-Months
Company Description
Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
RHHBY Stock 12 Month Forecast
Average Price Target
$49.67
▼(-5.39% Downside)
Technical Analysis
Ownership Overview
―
Insiders
0.57% Mutual Funds
0.10% Other Institutional Investors
99.30% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---